6
Oct
2022

Nobel for Bertozzi, Red Tree Eyes West Coast, & Doubling Down on Singapore

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
 

You may also like

Dimension Hauls In $800M, Arrowhead Nails Triglycerides, Tempus Buys Personalis
Merck Oral PSCK9 OK’d, Vertex Snaps Up Crinetics, Lilly Buys a Psychedelic
AbbVie Acquires Apogee, FDA Changes Tune on RegenxBio, & Merck Seizes TL1A Lead
Kardigan Continues IPO Trend & FDA Reconsiders UniQure and Moderna